Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
NCT07123649 is a phase 2 interventional trial sponsored by Dana-Farber Cancer Institute. As of 18 Nov 2026, it is recruiting participants. It studies Breast Cancer. The registry lists an enrollment of 364 participants at 1 site in 1 country. The registry lists a start date of 11 Sept 2025 and a primary completion date of 11 Sept 2027.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07123649 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Dana-Farber Cancer Institute |
| Enrollment | 364 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Breast Cancer |
| Start | 11 Sept 2025 |
| Primary completion | 11 Sept 2027 |
| Study completion | 11 Sept 2029 |
| Last update posted | 22 Apr 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Rachel Freedman, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dana-Farber Cancer Institute
Boston
Rachel Freedman, MD, MPHRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT07123649
Each answer restates registry values shown on this page.
What is NCT07123649?
NCT07123649 is a phase 2 interventional trial sponsored by Dana-Farber Cancer Institute. It studies Breast Cancer.
Is NCT07123649 recruiting?
As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT07123649?
The registry names Rachel Freedman, MD, MPH (principal investigator, Dana-Farber Cancer Institute) as the overall official.
Where does NCT07123649 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
When is NCT07123649 expected to complete?
The registry lists a primary completion date of 11 Sept 2027 and a study completion date of 11 Sept 2029. The sponsor last updated the record on 22 Apr 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.